Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

View the 50 largest pharmaceutical companies in the world listings here

UCB

UCB

Rank: 32

Brussels, Belgium
www.ucb.com

2020 Revenues ($USD) : $6,095,580,000
2020 Revenues (foreign currencies) : €5,347,000,000
2020 R&D spend : $1,767,718,200
2020 Number of Employees : 8,371
Fiscal Year End : 12/31/2020
Key People : Jean-Christophe Tellier, CEO

Founded nearly a century ago, UCB saw breakthrough successes in the 1980s and '90s with the creation of the antihistamine Zyrtec and the seizure treatment Keppra. By the 21st century, UCB was transforming into a pure biopharma company focusing on neurology and immunology disorders. The company continued to shop for acquisitions during the COVID-19 pandemic. After closing its $2.3 billion purchase of Ra Pharma and its potential myasthenia gravis treatment zilucoplan in April 2020, UCB acquired Engage Therapeutics and its investigational epileptic seizure treatment Staccato Alprazolam for $125 million in June 2020. UCB in November 2020 bought gene therapy Handl Therapeutics. Late last year, it also acquired a new campus in Windlesham, Surrey to bolster its R&D in the U.K. –CN

UCB facility

UCB biotech facility

Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50